<DOC>
	<DOCNO>NCT00202657</DOCNO>
	<brief_summary>The purpose study determine whether patient Parkinson 's disease treat pergolide high risk heart valve disease compare patient Parkinson 's disease treat pergolide .</brief_summary>
	<brief_title>Observational Study Heart Valve Disease Patients With Parkinson 's Disease Treated With Pergolide</brief_title>
	<detailed_description>Pergolide ergot dopamine receptor agonist demonstrate efficacy Parkinson 's disease . Last year , two study show pergolide induce unexpected heart valve disease potentially severe frequent . The late discovery unknown side effect dramatic consequence Parkinson 's disease management French drug agency ( AFFSAPS ) recently publish guideline prescription . Little known prevalence molecular mechanism lead adverse event . To determine prevalence , evolution , potential risk factor pergolide-induced heart valve disease , propose echocardiographic observational study parkinsonian patient take pergolide compare matched control . This clinical study perform Clinical Investigation Centre collaboration Institute Cardiology Salpétrière Hospital</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Pergolide</mesh_term>
	<criteria>Idiopathic Parkinson 's disease Hoehn Yahr score inferior equal 4 treat pergolide since 3 month ( pergolide group ) never treat pergolide ( control group ) Parkinson + syndrome , multiple system atrophy , supranuclear palsy hoehn yahr score equal 5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>parkinson 's disease</keyword>
	<keyword>pergolide</keyword>
	<keyword>heart valve disease</keyword>
</DOC>